Cytoarm is a cutting-edge cell therapy startup company founded in 2020. Led by world-class experts in both business and medical areas, Cytoarm is dedicated to developing novel T cell therapy for the treatment of untreatable diseases. Cytoarm's flagship product is the Armed-T cell platform, which provides a groundbreaking solution for untreatable cancer.

This next-generation T cell therapy offers a dosage and schedule that allows for multiple treatments with just one aphresis, eliminating the need for long-term hospitalization. The therapy involves a 30-minute infusion and is designed to arm your cells to fight against late-stage diseases. The brand's impressive pipeline includes the first candidate ready for an investigator-initiated clinical trial in end-stage untreatable metastatic colorectal cancer.

Additionally, three more candidates are under development for various untreatable diseases. Cytoarm's efforts have been recognized by winning the prestigious 2019 & 2020 National Innovation Awards. With a broad multi-national technology patent portfolio, Cytoarm is unlocking the next generation of T cell therapy to bring hope to patients with untreatable diseases